ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $303,019 | -11.4% | 3,236 | -15.6% | 0.00% | – |
| Q2 2023 | $342,095 | +61.4% | 3,833 | +120.8% | 0.00% | – |
| Q4 2022 | $212,018 | -0.5% | 1,736 | -24.1% | 0.00% | – |
| Q2 2022 | $213,000 | -22.5% | 2,288 | -2.3% | 0.00% | – |
| Q1 2022 | $275,000 | -25.3% | 2,343 | -14.4% | 0.00% | – |
| Q4 2021 | $368,000 | +5.7% | 2,736 | +25.4% | 0.00% | – |
| Q3 2021 | $348,000 | +15.2% | 2,181 | -5.1% | 0.00% | – |
| Q2 2021 | $302,000 | +3.1% | 2,298 | +1.1% | 0.00% | – |
| Q1 2021 | $293,000 | -24.3% | 2,273 | -2.2% | 0.00% | -100.0% |
| Q4 2020 | $387,000 | -0.8% | 2,323 | -8.1% | 0.00% | 0.0% |
| Q3 2020 | $390,000 | +5.1% | 2,529 | +0.8% | 0.00% | 0.0% |
| Q2 2020 | $371,000 | +30.6% | 2,508 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $284,000 | +10.5% | 2,518 | +12.8% | 0.00% | 0.0% |
| Q2 2019 | $257,000 | +4.0% | 2,233 | +6.2% | 0.00% | 0.0% |
| Q1 2019 | $247,000 | – | 2,102 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |